The biotech stock's lead therapy is looking at some competition.
Zai Lab's shares benefited from positive clinical trial news.
Find out if AbbVie can overcome sinking sales of its top-selling product.
The company has been a strong value stock but faces big changes this year.
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.
/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCORE™...
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....
Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel...
Genmab, Hologic, ServiceNow and Splunk have been highlighted in this Screen of The Week article.
These top-ranked stocks are likely to beat on the bottom line in their next releases. These stocks include Genmab (GMAB), Hologic (HOLX), ServiceNow (NOW) and Splunk (SPLK).